BackgroundTyphoid fever, also known as enteric fever, is a potentially fatal multisystemic illness caused primarily bySalmonella enterica,subspeciesentericaserovartyphiand, to a lesser extent, related serovarsparatyphiA, B, and C.The protean manifestations of typhoid fever make this disease a true diagnostic challenge. The classic presentation includes fever, malaise, diffuse abdominal pain, andconstipation. Untreated, typhoid fever is a grueling illness that may progress todelirium, obtundation, intestinal hemorrhage, bowel perforation, and death within 1 month of onset. Survivors may be left with long-term or permanent neuropsychiatric complications.S typhihas been a major human pathogen for thousands of years, thriving in conditions of poor sanitation, crowding, and social chaos. It may have responsible for the Great Plague of Athens at the end of the Pelopennesian War.[1]The nameS typhiis derived from the ancient Greektyphos,an ethereal smoke or cloud that was believed to cause disease and madness. In the advanced stages of typhoid fever, the patient's level of consciousness is truly clouded. Although antibiotics have markedly reduced the frequency of typhoid fever in the developed world, it remains endemic in developing countries.[2]S paratyphicauses the same syndrome but appears to be a relative newcomer. It may be taking over thetyphiniche, in part, because of immunological naivete among the population and incomplete coverage by vaccines that targettyphi.Note that some writers refer to the typhoid and paratyphoid fever as distinct syndromes caused by thetyphiversusparatyphiserovars, while others use the term typhoid fever for a disease caused by either one. We use the latter terminology. We refer to these serovars collectively as typhoidal salmonella.PathophysiologyAll pathogenicSalmonellaspecies, when present in the gut are engulfed by phagocytic cells, which then pass them through the mucosa and present them to the macrophages in the lamina propria. Nontyphoidal salmonellae are phagocytized throughout the distal ileum and colon. With toll-like receptor (TLR)5 and TLR-4/MD2/CD-14 complex, macrophages recognize pathogen-associated molecular patterns (PAMPs) such as flagella and lipopolysaccharides. Macrophages and intestinal epithelial cells then attract T cells and neutrophils with interleukin 8 (IL-8), causing inflammation and suppressing the infection.[3, 4]In contrast to the nontyphoidal salmonellae,S typhiand paratyphi enter the host's system primarily through the distal ileum.Theyhave specialized fimbriae that adhere to the epithelium over clusters of lymphoid tissue in the ileum (Peyer patches), the main relay point for macrophages traveling from the gut into the lymphatic system. The bacteria then induce their host macrophages to attract more macrophages.[3]S typhihas a Vi capsular antigen that masks PAMPs, avoiding neutrophil-based inflammation, while the most commonparatyphiserovar,paratyphi A, does not. This may explain the greater infectivity of typhi compared with most of its cousins.[5]Typhoidal salmonella co-opt the macrophages' cellular machinery for their own reproduction[6]as they are carried through the mesenteric lymph nodes to the thoracic duct and the lymphatics and then through to the reticuloendothelial tissues of the liver, spleen, bone marrow, and lymph nodes. Once there, they pause and continue to multiply until some critical density is reached. Afterward, the bacteria induce macrophage apoptosis, breaking out into the bloodstream to invade the rest of the body.[4]The bacteria then infect the gallbladder via either bacteremia or direct extension of infected bile. The result is that the organism re-enters the gastrointestinal tract in the bile and reinfects Peyer patches. Bacteria that do not reinfect the host are typically shed in the stool and are then available to infect other hosts.[2, 4]See the image below.

Chronic carriers are responsible for much of the transmission of the organism. While asymptomatic, they may continue to shed bacteria in their stool for decades. The organisms sequester themselves either as a biofilm on gallstones or gallbladder epithelium or, perhaps, intracellularly, within the epithelium itself.[7]The bacteria excreted by a single carrier may have multiple genotypes, making it difficult to trace an outbreak to its origin.[8]Risk factorsTyphoidal salmonella have no nonhuman vectors. An inoculum as small as 100,000 organisms oftyphicauses infection in more than 50% of healthy volunteers.[9]Paratyphirequires a much higher inoculum to infect, and it is less endemic in rural areas. Hence, the patterns of transmission are slightly different.The following are modes of transmission of typhoidal salmonella: Oral transmission via food or beverages handled by an often asymptomatic individuala carrierwho chronically sheds the bacteria through stool or, less commonly, urine Hand-to-mouth transmission after using a contaminated toilet and neglecting hand hygiene Oral transmission via sewage-contaminated water or shellfish (especially in the developing world).[10, 11, 12]Paratyphiis more commonly transmitted in food from street vendors. It is believed that some such foods provide a friendly environment for the microbe.Paratyphiis more common among newcomers to urban areas, probably because they tend to be immunologically nave to it. Also, travellers get little or no protection againstparatyphifrom the current typhoid vaccines, all of which targettyphi.[13, 14]Typhoidal salmonella are able to survive a stomach pH as low as 1.5. Antacids, histamine-2 receptor antagonists (H2 blockers), proton pump inhibitors, gastrectomy, and achlorhydria decrease stomach acidity and facilitateS typhiinfection.[4]HIV/AIDSis clearly associated with an increased risk of nontyphoidalSalmonellainfection; however, the data and opinions in the literature as to whether this is true forS typhior paratyphi infection are conflicting. If an association exists, it is probably minor.[15, 16, 17, 18]Other risk factors for typhoid fever include various genetic polymorphisms. These risk factors often also predispose to other intracellular pathogens. For instance,PARK2andPACGRcode for a protein aggregate that is essential for breaking down the bacterial signaling molecules that dampen the macrophage response. Polymorphisms in their shared regulatory region are found disproportionately in persons infected withMycobacterium lepraeandS typhi.[11]On the other hand, protective host mutations also exist. The fimbriae ofS typhibind in vitro to cystic fibrosis transmembrane conductance receptor (CFTR), which is expressed on the gut membrane. Two to 5% of white persons are heterozygous for the CFTR mutation F508del, which is associated with a decreased susceptibility to typhoid fever, as well as tocholeraandtuberculosis. The homozygous F508del mutation in CFTR is associated with cystic fibrosis. Thus, typhoid fever may contribute to evolutionary pressure that maintains a steady occurrence of cystic fibrosis, just asmalariamaintainssickle cell diseasein Africa.[19, 20]As the middle class in south Asia grows, some hospitals there are seeing a large number of typhoid fever cases among relatively well-off university students who live in group households with poor hygiene.[21]American clinicians should keep this in mind, as members of this cohort often come to the United States for advanced degrees.EpidemiologyFrequencyUnited StatesSince 1900, improved sanitation and successful antibiotic treatment have steadily decreased the incidence of typhoid fever in the United States. In 1920, 35,994 cases of typhoid fever were reported. In 2006, there were 314.Between 1999 and 2006, 79% of typhoid fever cases occurred in patients who had been outside of the country within the preceding 30 days. Two thirds of these individuals had just journeyed from the Indian subcontinent. The 3 known outbreaks of typhoid fever within the United States were traced to imported food or to a food handler from an endemic region. Remarkably, only 17% of cases acquired domestically were traced to a carrier.[22]InternationalTyphoid fever occurs worldwide, primarily in developing nations whose sanitary conditions are poor. Typhoid fever is endemic in Asia, Africa, Latin America, the Caribbean, and Oceania, but 80% of cases come from Bangladesh, China, India, Indonesia, Laos, Nepal, Pakistan, or Vietnam.[23]Within those countries, typhoid fever is most common in underdeveloped areas. Typhoid fever infects roughly 21.6 million people (incidence of 3.6 per 1,000 population) and kills an estimated 200,000 people every year.[24]In the United States, most cases of typhoid fever arise in international travelers. The average yearly incidence of typhoid fever per million travelers from 1999-2006 by county or region of departure was as follows:[22] Canada - 0 Western Hemisphere outside Canada/United States - 1.3 Africa - 7.6 Asia - 10.5 India - 89 (122 in 2006) Total (for all countries except Canada/United States) - 2.2Mortality/MorbidityWith prompt and appropriate antibiotic therapy, typhoid fever is typically a short-term febrile illness requiring a median of 6 days of hospitalization. Treated, it has few long-term sequelae and a 0.2% risk of mortality.[22]Untreated typhoid fever is a life-threatening illness of several weeks' duration with long-term morbidity often involving the central nervous system. The case fatality rate in the United States in the pre-antibiotic era was 9%-13%.[25]RaceTyphoid fever has no racial predilection.SexFifty-four percent of typhoid fever cases in the United States reported between 1999 and 2006 involved males.[22]AgeMost documented typhoid fever cases involve school-aged children and young adults. However, the true incidence among very young children and infants is thought to be higher. The presentations in these age groups may be atypical, ranging from a mild febrile illness to severe convulsions, and theS typhiinfection may go unrecognized. This may account for conflicting reports in the literature that this group has either a very high or a very low rate of morbidity and mortality.[21, 26]Proceed toClinical PresentationHistoryA severe nonspecific febrile illness in a patient who has been exposed to typhoidal salmonella should always raise the diagnostic possibility of typhoid fever (enteric fever).Classic typhoid fever syndromeThe clinical syndromes associated withS typhiandparatyphiare indistinguishable. Typhoid fever begins 7-14 days after ingestion of the organism.The fever pattern is stepwise, characterized by a rising temperature over the course of each day that drops by the subsequent morning. The peaks and troughs rise progressively over time.Over the course of the first week of illness, the notorious gastrointestinal manifestations of the disease develop. These include diffuse abdominal pain and tenderness and, in some cases, fierce colicky right upper quadrant pain. Monocytic infiltration inflames Peyer patches and narrows the bowel lumen, causing constipation that lasts the duration of the illness. The individual then develops a dry cough, dull frontal headache, delirium, and an increasingly stuporous malaise.[2]At approximately the end of the first week of illness, the fever plateaus at 103-104F (39-40C). The patient develops rose spots, which are salmon-colored, blanching, truncal, maculopapules usually 1-4 cm wide and fewer than 5 in number; these generally resolve within 2-5 days.[2]These are bacterial emboli to the dermis and occasionally develop in persons withshigellosisor nontyphoidalsalmonellosis.[27]During the second week of illness, the signs and symptoms listed above progress. The abdomen becomes distended, and soft splenomegaly is common. Relative bradycardia and dicrotic pulse (double beat, the second beat weaker than the first) may develop.In the third week, the still febrile individual grows more toxic and anorexic with significant weight loss. The conjunctivae are infected, and the patient is tachypneic with a thready pulse and crackles over the lung bases. Abdominal distension is severe. Some patients experience foul, green-yellow, liquid diarrhea (pea soup diarrhea). The individual may descend into the typhoid state, which is characterized by apathy, confusion, and even psychosis. Necrotic Peyer patches may cause bowel perforation and peritonitis. This complication is often unheralded and may be masked by corticosteroids. At this point, overwhelming toxemia,myocarditis, or intestinal hemorrhage may cause death.If the individual survives to the fourth week, the fever, mental state, and abdominal distension slowly improve over a few days. Intestinal and neurologic complications may still occur in surviving untreated individuals. Weight loss and debilitating weakness last months. Some survivors become asymptomaticS typhicarriers and have the potential to transmit the bacteria indefinitely.[21, 28, 29, 2, 4]Various presentations of typhoid feverThe clinical course of a given individual with typhoid fever may deviate from the above description of classic disease. The timing of the symptoms and host response may vary based on geographic region, race factors, and the infecting bacterial strain. The stepladder fever pattern that was once the hallmark of typhoid fever now occurs in as few as 12% of cases. In most contemporary presentations of typhoid fever, the fever has a steady insidious onset.Young children, individuals with AIDS, and one third of immunocompetent adults who develop typhoid fever develop diarrhea rather than constipation. In addition, in some localities, typhoid fever is generally more apt to cause diarrhea than constipation.Atypical manifestations of typhoid fever include isolated severe headaches that may mimicmeningitis, acute lobar pneumonia, isolated arthralgias, urinary symptoms, severe jaundice, or fever alone. Some patients, especially in India and Africa, present primarily with neurologic manifestations such asdeliriumor, in extremely rare cases, parkinsonian symptoms or Guillain-Barr syndrome. Other unusual complications include pancreatitis,[30]meningitis,orchitis, osteomyelitis, and abscesses anywhere on the body.[2]Table 1. Incidence and Timing of Various Manifestations of Untreated Typhoid Fever[2, 31, 32, 33, 34, 35](Open Table in a new window)ever[2, 31, 32, 33, 34, 35](Open Table in a new window)IncubationWeek 1Week 2Week 3Week 4Post

SystemicRecovery phase or death (15% of untreated cases)10%-20% relapse; 3%-4% chronic carriers;

long-term neurologic sequelae (extremely rare);

gallbladder cancer (RR=167; carriers)

Stepladder fever pattern or insidious onset feverVery commonaVery common

Acute high feverVery rareb

ChillsAlmost allc

RigorsUncommon

AnorexiaAlmost all

DiaphoresisVery common

Neurologic

MalaiseAlmost allAlmost allTyphoid state (common)

InsomniaVery common

Confusion/deliriumCommondVery common

PsychosisVery rareCommon

CatatoniaVery rare

Frontal headache

(usually mild)

Very common

Meningeal signsRareeRare

ParkinsonismVery rare

Ear, nose, and throat

Coated tongueVery common

Sore throatf

Pulmonary

Mild coughCommon

Bronchitic coughCommon

RalesCommon

PneumoniaRare (lobar)RareCommon

(basal)

Cardiovascular

Dicrotic pulseRareCommon

MyocarditisRare

PericarditisExtremely rareg

ThrombophlebitisVery rare

Gastrointestinal

ConstipationVery commonCommon

DiarrheaRareCommon (pea soup)

Bloating with tympanyVery common (84%)[35]

Diffuse mild abdominal painVery common

Sharp right lower quadrant painRare

Gastrointestinal hemorrhageVery rare; usually traceVery common

intestinal perforationRare

HepatosplenomegalyCommon

JaundiceCommon

Gallbladder painVery rare

Urogenital

Urinary retentionCommon

HematuriaRare

Renal painRare

Musculoskeletal

MyalgiasVery rare

ArthralgiasVery rare

Rheumatologic

Arthritis (large joint)Extremely rare

Dermatologic

Rose spotsRare

Miscellaneous

Abscess (anywhere)Extremely rareExtremely rareExtremely rare

aVery common: Symptoms occur in well over half of cases (approximately 65%-95%).

bVery rare: Symptoms occur in less than 5% of cases.

cAlmost all: Symptoms occur in almost all cases.

dCommon: Symptoms occur in 35%-65% of cases.

eRare: Symptoms occur in 5%-35% of cases.

fBlank cells: No mention of the symptom at that phase was found in the literature.

gExtremely rare: Symptoms have been described in occasional case reports.

Treated typhoid feverIf appropriate treatment is initiated within the first few days of full-blown illness, the disease begins to remit after about 2 days, and the patient's condition markedly improves within 4-5 days. Any delay in treatment increases the likelihood of complications and recovery time.PhysicalSee History.CausesS typhiandSalmonella paratyphicause typhoid fever.

Differential Diagnoses Abdominal Abscess Amebic Hepatic Abscesses Appendicitis Brucellosis Dengue Fever Influenza Leishmaniasis Malaria Rickettsial diseases Toxoplasmosis Tuberculosis Tularemia Typhus

Laboratory StudiesThe diagnosis of typhoid fever (enteric fever) is primarily clinical.Importantly, the reported sensitivities of tests forS typhivary greatly in the literature, even among the most recent articles and respected journals.CultureThe criterion standard for diagnosis of typhoid fever has long been culture isolation of the organism. Cultures are widely considered 100% specific.Culture of bone marrow aspirate is 90% sensitive until at least 5 days after commencement of antibiotics. However, this technique is extremely painful, which may outweigh its benefit.[36]Blood, intestinal secretions (vomitus or duodenal aspirate), and stool culture results are positive forS typhiin approximately 85%-90% of patients with typhoid fever who present within the first week of onset. They decline to 20%-30% later in the disease course. In particular, stool culture may be positive forS typhiseveral days after ingestion of the bacteria secondary to inflammation of the intraluminal dendritic cells. Later in the illness, stool culture results are positive because of bacteria shed through the gallbladder.Multiple blood cultures (>3) yield a sensitivity of 73%-97%. Large-volume (10-30 mL) blood culture and clot culture may increase the likelihood of detection.[37]Stool culture alone yields a sensitivity of less than 50%, and urine culture alone is even less sensitive. Cultures of punch-biopsy samples of rose spots reportedly yield a sensitivity of 63% and may show positive results even after administration of antibiotics. A single rectal swab culture upon hospital admission can be expected to detectS typhiin 30%-40% of patients.S typhihas also been isolated from the cerebrospinal fluid, peritoneal fluid, mesenteric lymph nodes, resected intestine, pharynx, tonsils, abscess, and bone, among others.Bone marrow aspiration and blood are cultured in a selective medium (eg, 10% aqueous oxgall) or a nutritious medium (eg, tryptic soy broth) and are incubated at 37C for at least 7 days. Subcultures are made daily to one selective medium (eg, MacConkey agar) and one inhibitory medium (eg,Salmonella-Shigellaagar). Identification of the organism with these conventional culture techniques usually takes 48-72 hours from acquisition.Table 2. Sensitivities of Cultures[2, 37, 38, 39](Open Table in a new window)IncubationWeek 1Week 2Week 3Week 4

Bone marrow aspirate (0.5-1 mL)90% (may decrease after 5 d of antibiotics)

Blood (10-30 mL), stool, or duodenal aspirate culture40%-80%~20%Variable (20%-60%)

Urine25%-30%, timing unpredictable

Polymerase chain reactionPolymerase chain reaction (PCR) has been used for the diagnosis of typhoid fever with varying success. Nested PCR, which involves two rounds of PCR using two primers with different sequences within the H1-d flagellin gene ofS typhi, offers the best sensitivity and specificity. Combining assays of blood and urine, this technique has achieved a sensitivity of 82.7% and reported specificity of 100%. However, no type of PCR is widely available for the clinical diagnosis of typhoid fever.[40, 41]Specific serologic testsAssays that identifySalmonellaantibodies or antigens support the diagnosis of typhoid fever, but these results should be confirmed with cultures or DNA evidence.The Widal test was the mainstay of typhoid fever diagnosis for decades. It is used to measure agglutinating antibodies against H and O antigens ofS typhi. Neither sensitive nor specific, the Widal test is no longer an acceptable clinical method.Indirect hemagglutination, indirect fluorescent Vi antibody, and indirect enzyme-linked immunosorbent assay (ELISA) for immunoglobulin M (IgM) and IgG antibodies toS typhipolysaccharide, as well as monoclonal antibodies againstS typhiflagellin,[42]are promising, but the success rates of these assays vary greatly in the literature.Other nonspecific laboratory studiesMost patients with typhoid fever are moderately anemic, have an elevated erythrocyte sedimentation rate (ESR), thrombocytopenia, and relative lymphopenia.Most also have a slightly elevated prothrombin time (PT) and activated partial thromboplastin time (aPTT) and decreased fibrinogen levels.Circulating fibrin degradation products commonly rise to levels seen in subclinicaldisseminated intravascular coagulation(DIC).Liver transaminase and serum bilirubin values usually rise to twice the reference range.Mild hyponatremia and hypokalemia are common.A serum alanine amino transferase (ALT)tolactate dehydrogenase (LDH) ratio of more than 9:1 appears to be helpful in distinguishing typhoid from viral hepatitis. A ratio of greater than 9:1 supports a diagnosis of acute viral hepatitis, while ratio of less than 9:1 supports typhoid hepatitis.[43]Imaging StudiesRadiography: Radiography of the kidneys, ureters, and bladder (KUB) is useful if bowel perforation (symptomatic or asymptomatic) is suspected.CT scanning and MRI: These studies may be warranted to investigate for abscesses in the liver or bones, among other sites.ProceduresBone marrow aspiration: The most sensitive method of isolatingS typhiis BMA culture (see Lab Studies).Histologic FindingsThe hallmark histologic finding in typhoid fever is infiltration of tissues by macrophages (typhoid cells) that contain bacteria, erythrocytes, and degenerated lymphocytes. Aggregates of these macrophages are called typhoid nodules, which are found most commonly in the intestine, mesenteric lymph nodes, spleen, liver, and bone marrow but may be found in the kidneys, testes, and parotid glands. In the intestines, 4 classic pathologic stages occur in the course of infection: (1) hyperplastic changes, (2) necrosis of the intestinal mucosa, (3) sloughing of the mucosa, and (4) the development of ulcers. The ulcers may perforate into the peritoneal cavity.In the mesenteric lymph nodes, the sinusoids are enlarged and distended by large collections of macrophages and reticuloendothelial cells. The spleen is enlarged, red, soft, and congested; its serosal surface may have a fibrinous exudate. Microscopically, the red pulp is congested and contains typhoid nodules. The gallbladder is hyperemic and may show evidence ofcholecystitis. Liver biopsy specimens from patients with typhoid fever often show cloudy swelling, balloon degeneration with vacuolation of hepatocytes, moderate fatty change, and focal typhoid nodules. Intact typhoid bacilli can be observed at these sites.[2, 4]StagingThe proper treatment approach to typhoid fever depends on whether the illness is complicated or uncomplicated. Complicated typhoid fever is characterized by melena (3% of all hospitalized patients with typhoid fever), serious abdominal discomfort, intestinal perforation, marked neuropsychiatric symptoms, or other severe manifestations. Depending on the adequacy of diagnosis and treatment, complicated disease may develop in up to 10% of treated patients. Delirium, obtundation, stupor, coma, or shock demands a particularly aggressive approach (see Treatment).[34]

Medical CareIf a patient presents with unexplained symptoms described in Table 1 within 60 days of returning from an typhoid fever (enteric fever) endemic area or following consumption of food prepared by an individual who is known to carry typhoid, broad-spectrum empiric antibiotics should be started immediately. Treatment should not be delayed for confirmatory tests since prompt treatment drastically reduces the risk of complications and fatalities. Antibiotic therapy should be narrowed once more information is available.Compliant patients with uncomplicated disease may be treated on an outpatient basis. They must be advised to use strict handwashing techniques and to avoid preparing food for others during the illness course. Hospitalized patients should be placed in contact isolation during the acute phase of the infection. Feces and urine must be disposed of safely.Surgical CareSurgery is usually indicated in cases of intestinal perforation. Most surgeons prefer simple closure of the perforation with drainage of the peritoneum. Small-bowel resection is indicated for patients with multiple perforations.If antibiotic treatment fails to eradicate the hepatobiliary carriage, the gallbladder should be resected. Cholecystectomy is not always successful in eradicating the carrier state because of persisting hepatic infection.ConsultationsAn infectious disease specialist should be consulted. Consultation with a surgeon is indicated upon suspected gastrointestinal perforation, serious gastrointestinal hemorrhage, cholecystitis, or extraintestinal complications (arteritis, endocarditis, organ abscesses).DietFluids and electrolytes should be monitored and replaced diligently. Oral nutrition with a soft digestible diet is preferable in the absence of abdominal distension or ileus.ActivityNo specific limitations on activity are indicated for patients with typhoid fever. As with most systemic diseases, rest is helpful, but mobility should be maintained if tolerable. The patient should be encouraged to stay home from work until recovery.

AntibioticsClass SummaryDefinitive treatment of typhoid fever (enteric fever) is based on susceptibility. As a general principle of antimicrobial treatment, intermediate susceptibility should be regarded as equivalent to resistance. Between 1999 and 2006, 13% ofS typhiisolates collected in the United States were multidrug resistant.Until susceptibilities are determined, antibiotics should be empiric, for which there are various recommendations. The authors of this article recommend combination treatment with ceftriaxone and ciprofloxacin when neither the sensitivities nor the geographical origin of the bacteria is known.The particular sensitivity pattern of the organism in its area of acquisition should be the major basis of empiric antibiotic choice. It may soon become necessary to treat all cases presumptively for multidrug resistance until sensitivities are obtained.History of antibiotic resistanceChloramphenicol was used universally to treat typhoid fever from 1948 until the 1970s, when widespread resistance occurred. Ampicillin and trimethoprim-sulfamethoxazole (TMP-SMZ) then became treatments of choice. However, in the late 1980s, someS typhiandS paratyphistrains (multidrug resistant [MDR]S typhiorS paratyphi) developed simultaneous plasmid-mediated resistance to all three of these agents.Fluoroquinolones are highly effective against susceptible organisms, yielding a better cure rate than cephalosporins. Unfortunately, resistance to first-generation fluoroquinolones is widespread in many parts of Asia.In recent years, third-generation cephalosporins have been used in regions with high fluoroquinolone resistance rates, particularly in south Asia and Vietnam. Unfortunately, sporadic resistance has been reported, so it is expected that these will become less useful over time.[44]Mechanisms of antibiotic resistanceThe genes for antibiotic resistance inS typhiandS paratyphiare acquired fromEscherichia coliand other gram-negative bacteria via plasmids. The plasmids contain cassettes of resistance genes that are incorporated into a region of theSalmonellagenome called an integron. Some plasmids carry multiple cassettes and immediately confer resistance to multiple classes of antibiotics. This explains the sudden appearance of MDR strains ofS typhiandS paratyphi,often without intermediate strains that have less-extensive resistance.The initial strains of antibiotic-resistantS typhiandS paratyphicarried chloramphenicol acetyltransferase type I, which encodes an enzyme that inactivates chloramphenicol via acetylation. MDR strains may carry dihydrofolate reductase type VII, which confers resistance to trimethoprim. Interestingly, in areas where these drugs have fallen out of use,S typhihas reverted to wild type, and they are often more effective than newer agents.[45, 46, 47, 35]Resistance to fluoroquinolones is evolving in an ominous direction. Fluoroquinolones target DNA gyrase and topoisomerase IV, bacterial enzymes that are part of a complex that uncoils and recoils bacterial DNA for transcription.[48]S typhimost commonly develops fluoroquinolone resistance through specific mutations ingyrAandparC,which code for the binding region of DNA gyrase and topoisomerase IV, respectively.A single point mutationgyrAconfers partial resistance. If a secondgyrApoint mutation is added, the resistance increases somewhat. However, a mutation inparCadded to a singlegyrAmutation confers full in vitro resistance to first-generation fluoroquinolones. Clinically, these resistant strains show a 36% failure rate when treated with a first-generation fluoroquinolone such as ciprofloxacin.[49]The risk of relapse after bacterial clearance is higher in both partially and fully resistant strains than in fully susceptible strains.[23]The third-generation fluoroquinolone gatifloxacin appears to be highly effective against all known clinical strains ofS typhiboth in vitro and in vivo. due to its unique interface withgyrA. It achieves better results than cephalosporins even among strains that are considered fluoroquinolone resistant. However, gatifloxacin is no longer on the market in the United States, and its use cannot be generalized to any other member of the class.[50, 51]In any case, as gatifloxacin replaces older fluoroquinolones in high-prevalence resistance is bound to emerge. Any two of a number ofgyrAmutations, when added to theparCmutation, confer full in vitro resistance. Although such a combination has yet to be discovered in vivo, all of these mutations exist in various clinic strains, and it seems highly likely that a gatifloxacin-resistant one will be encountered clinically if selective pressure with fluoroquinolones continues to be exerted.[49]Geography of resistanceAmongS typhiisolates obtained in the United States between 1999 and 2006, 43% were resistant to at least one antibiotic.Nearly half ofS typhiisolates found in the United States now come from travelers to the Indian subcontinent, where fluoroquinolone resistance is endemic (see Table 3). The rate of fluoroquinolone resistance in south and Southeast Asia and, to some extent, in East Asia is generally high and rising (see Table 3). Susceptibility to chloramphenicol, TMP-SMZ, and ampicillin in South Asia is rebounding. In Southeast Asia, MDR strains remain predominant, and some acquired resistance to fluoroquinolones by the early 2000s.The most recent professional guideline for the treatment of typhoid fever in south Asia was issued by the Indian Association of Pediatrics (IAP) in October 2006. Although these guidelines were published for pediatric typhoid fever, the authors feel that they are also applicable to adult cases. For empiric treatment of uncomplicated typhoid fever, the IAP recommends cefixime and, as a second-line agent, azithromycin. For complicated typhoid fever, they recommend ceftriaxone. Aztreonam and imipenem are second-line agents for complicated cases.[52]The authors believe that the IAP recommendations apply to empiric treatments of typhoid fever in both adults and children.In high-prevalence areas outside the areas discussed above, the rate of intermediate sensitivity or resistance to fluoroquinolones is 3.7% in the Americas (P=.132), 4.7% (P=.144) in sub-Saharan Africa, and 10.8% (P=.706) in the Middle East. Therefore, for strains that originate outside of south or Southeast Asia, the WHO recommendations may still be validthat uncomplicated disease should be treated empirically with oral ciprofloxacin and complicated typhoid fever from these regions should be treated with intravenous ciprofloxacin.[44, 47, 53, 24, 54]Resistance in the United StatesIn the United States in 2012, 68% ofS typhiisolates and 95% ofS paratyphiisolates were fully resistant to nalidixic acid. While full resistance to ciprofloxacin was considerably less, intermediate susceptibilities to ciprofloxacin in both organisms closely matched resistance to nalidixic acid. Note that nalidixic acid is a nontherapeutic drug that is used outside of the United States as a stand-in for fluoroquinolones in sensitivity assays. In the United States, it is still used specifically forS typhiinfection.[44, 22]The rate of multidrug resistance in 2012 was 9% inS typhiand 0% inS paratyphi. (Multidrug-resistantS typhiis, by definition, resistant to the original first-line agents, ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole.)There have been no cases of ceftriaxone-resistantS typhiorS paratyphidocumented in the United States, at least since 2003.[55]Antibiotic resistance is a moving target. Reports are quickly outdated, and surveys of resistance may have limited geographic scope. Therefore, any recommendation regarding antibiotic treatment must be taken with a grain of salt. However, in the authors' opinion, if the origin of the infection is unknown, the combination of a first-generation fluoroquinolone and a third-generation cephalosporin should be used. This allows for most effective clearance if the organism is fluoroquinolone-susceptible but still covers strains that are not.Table 3. Antibiotic Recommendations by Origin and Severity(Open Table in a new window)LocationSeverityFirst-Line AntibioticsSecond-Line Antibiotics

South Asia, East Asia[52]

[56, 45]

UncomplicatedCefixime POAzithromycin PO

ComplicatedCeftriaxone IVor

Cefotaxime IV

Aztreonam IVor

Imipenem IV

Eastern Europe, Middle East, sub-Saharan Africa, South America[53, 57]UncomplicatedCiprofloxacin POor

Ofloxacin PO

Cefixime POor

Amoxicillin POor

TMP-SMZ PO

or Azithromycin PO

ComplicatedCiprofloxacin IVor

Ofloxacin IV

Ceftriaxone IVor

Cefotaxime IVor

Ampicillin IV

or

TMP-SMZ IV

Unknown geographic origin or Southeast Asia[58, 52]

[56, 45, 53, 57]

UncomplicatedCefixime POplus

Ciprofloxacin POor

Ofloxacin PO

Azithromycin PO*

ComplicatedCeftriaxone IVor

Cefotaxime IV,plus

Ciprofloxacin IVor

Ofloxacin IV

Aztreonam IVor

Imipenem IV,plus

Ciprofloxacin IV

or

Ofloxacin IV

*Note that the combination of azithromycin and fluoroquinolones is not recommended because it may cause QT prolongation and is relatively contraindicated.

Future directionsA meta-analysis found that azithromycin appeared to be superior to fluoroquinolones and ceftriaxone with lower rates of clinical failure and relapse respectively. Although the data did not permit firm conclusions, if further studies confirm the trend, azithromycin could become a first-line treatment.[59]View full drug informationChloramphenicol (Chloromycetin)Binds to 50S bacterial-ribosomal subunits and inhibits bacterial growth by inhibiting protein synthesis. Effective against gram-negative and gram-positive bacteria. Since its introduction in 1948, has proven to be remarkably effective for enteric fever worldwide. For sensitive strains, still most widely used antibiotic to treat typhoid fever. In the 1960s,S typhi strains with plasmid-mediated resistance to chloramphenicol began to appear and later became widespread in many endemic countries of the Americas and Southeast Asia, highlighting need for alternative agents.Produces rapid improvement in patient's general condition, followed by defervescence in 3-5 d. Reduced preantibiotic-era case-fatality rates from 10%-15% to 1%-4%. Cures approximately 90% of patients. Administered PO unless patient is nauseous or experiencing diarrhea; in such cases, IV route should be used initially. IM route should be avoided because it may result in unsatisfactory blood levels, delaying defervescence.View full drug informationAmoxicillin (Trimox, Amoxil, Biomox)Interferes with synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria. At least as effective as chloramphenicol in rapidity of defervescence and relapse rate. Convalescence carriage occurs less commonly than with other agents when organisms are fully susceptible. Usually given PO with a daily dose of 75-100 mg/kg tid for 14 d.View full drug informationTrimethoprim and sulfamethoxazole (Bactrim DS, Septra)Inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid. Antibacterial activity of TMP-SMZ includes common urinary tract pathogens, exceptPseudomonas aeruginosa. As effective as chloramphenicol in defervescence and relapse rate. Trimethoprim alone has been effective in small groups of patients.View full drug informationCiprofloxacin (Cipro)Fluoroquinolone with activity against pseudomonads, streptococci, MRSA,Staphylococcus epidermidis,and most gram-negative organisms but no activity against anaerobes. Inhibits bacterial DNA synthesis and, consequently, growth. Continue treatment for at least 2 d (7-14 d typical) after signs and symptoms have disappeared. Proven to be highly effective for typhoid and paratyphoid fevers. Defervescence occurs in 3-5 d, and convalescent carriage and relapses are rare. Other quinolones (eg, ofloxacin, norfloxacin, pefloxacin) usually are effective. If vomiting or diarrhea is present, should be given IV. Fluoroquinolones are highly effective against multiresistant strains and have intracellular antibacterial activity.Not currently recommended for use in children and pregnant women because of observed potential for causing cartilage damage in growing animals. However, arthropathy has not been reported in children following use of nalidixic acid (an earlier quinolone known to produce similar joint damage in young animals) or in children with cystic fibrosis, despite high-dose treatment.Cefotaxime (Claforan)Arrests bacterial cell wall synthesis, which inhibits bacterial growth. Third-generation cephalosporin with gram-negative spectrum. Lower efficacy against gram-positive organisms. Excellent in vitro activity againstS typhiand other salmonellae and has acceptable efficacy in typhoid fever. Only IV formulations are available. Recently, emergence of domestically acquired ceftriaxone-resistantSalmonellainfections has been described.View full drug informationAzithromycin (Zithromax)Treats mild to moderate microbial infections. Administered PO at 10 mg/kg/d (not exceeding 500 mg), appears to be effective to treat uncomplicated typhoid fever in children 4-17 y. Confirmation of these results could provide an alternative for treatment of typhoid fever in children in developing countries, where medical resources are scarce.View full drug informationCeftriaxone (Rocephin)Third-generation cephalosporin with broad-spectrum gram-negative activity against gram-positive organisms; Excellent in vitro activity againstS typhiand other salmonellae.Cefoperazone (Cefobid)Discontinued in the United States. Third-generation cephalosporin with gram-negative spectrum. Lower efficacy against gram-positive organisms.View full drug informationOfloxacin (Floxin)A pyridine carboxylic acid derivative with broad-spectrum bactericidal effect.View full drug informationLevofloxacin (Levaquin)For pseudomonal infections and infections due to multidrug-resistant gram-negative organisms.CorticosteroidsClass SummaryDexamethasone may decrease the likelihood of mortality in severe typhoid fever cases complicated by delirium, obtundation, stupor, coma, or shock if bacterial meningitis has been definitively ruled out by cerebrospinal fluid studies. To date, the most systematic trial of this has been a randomized controlled study in patients aged 3-56 years with severe typhoid fever who were receiving chloramphenicol therapy. This study compared outcomes in 18 patients given placebo with outcomes in 20 patients given dexamethasone 3 mg/kg IV over 30 minutes followed by dexamethasone 1 mg/kg every 6 hours for 8 doses. The fatality rate in the dexamethasone arm was 10% versus 55.6% in the placebo arm (P=.003).[60]Nonetheless, this point is still debated. A 2003 WHO statement endorsed the use of steroids as described above, but reviews by eminent authors in theNew England Journal of Medicine(2002)[4]and theBritish Medical Journal(2006)[61]do not refer to steroids at all. A 1991 trial compared patients treated with 12 doses of dexamethasone 400 mg or 100 mg to a retrospective cohort in whom steroids were not administered. This trial found no difference in outcomes among the groups.[62]The data are sparse, but the authors of this article agree with the WHO that dexamethasone should be used in cases of severe typhoid fever.View full drug informationDexamethasone (Decadron)Prompt administration of high-dose dexamethasone reduces mortality in patients with severe typhoid fever without increasing incidence of complications, carrier states, or relapse among survivors.Further Inpatient CareIf treated with well-selected antibiotics, patients with typhoid fever (enteric fever) should defervesce within 3-5 days. However, patients with complicated typhoid fever should finish their course intravenously and should remain in the hospital if unable to manage this at home.Patients with complicated typhoid fever should be admitted through the acute phase of the illness. Uncomplicated cases are generally treated on an outpatient basis unless the patient is a public health risk or cannot be fully monitored outside the home.Further Outpatient CareAfter discharge, patients should be monitored for relapse or complications for 3 months after treatment has commenced.Five percent to 10% of patients treated with antibiotics experience relapse of typhoid fever after initial recovery. Relapses typically occur approximately 1 week after therapy is discontinued, but relapse after 70 days has been reported. In these cases, the blood culture results are again positive, and high serum levels of H, O, and Vi antibodies and rose spots may reappear.A relapse of typhoid fever is generally milder and of shorter duration than the initial illness. In rare cases, second or even third relapses occur. Notably, the relapse rate is much lower following treatment with the new quinolone drugs, which have effective intracellular penetration.S typhiandS paratyphirarely develop antibiotic resistance during treatment. If an antibiotic has been chosen according to sensitivities, relapse should dictate a search for anatomic, pathologic, or genetic predispositions rather than for an alternate antibiotic.Previous infection does not confer immunity. In any suspected relapse, infection with a different strain should be ruled out.Depending on the antibiotic used, between 0% and 5.9% of treated patients become chronic carriers. In some cases, the organism evades antibiotics by sequestering itself withingallstonesorSchistosoma haematobiumorganisms that are infecting the bladder. From there, it is shed in stool or urine, respectively. If present, these diseases must be cured before the bacterium can be eliminated.Untreated survivors of typhoid fever may shed the bacterium in the feces for up to 3 months. Therefore, after disease resolution, 3 stool cultures in one-month intervals should be performed to rule out a carrier state. Concurrent urinary cultures should be considered.Deterrence/PreventionTravelers to endemic countries should avoid raw unpeeled fruits or vegetables since they may have been prepared with contaminated water and should not buy food from street vendors; in addition, they should drink only boiled water.In endemic countries, the most cost-effective strategy for reducing the incidence of typhoid fever is the institution of public health measures to ensure safe drinking water and sanitary disposal of excreta. The effects of these measures are long-term and reduce the incidence of other enteric infections, which are a major cause of morbidity and mortality in those areas.VaccinesIn endemic areas, mass immunization with typhoid vaccines at regular intervals considerably reduces the incidence of infections.Routine typhoid vaccination is not recommended in the United States but is indicated for travelers to endemic areas, persons with intimate exposure to a documentedS typhicarrier (eg, household contacts of chronic carriers, defined as persons with excretion ofS typhiin urine or stool 1 year), and microbiology laboratory personnel who frequently work withS typhi. In their 2015 recommendations, the Advisory Committee on Immunization Practices in the US recommends that travelers to countries with a high prevalence of typhoid and recognized risk for exposure toStyphishould be vaccinated against typhoid, even if they are staying with friends or relatives or only traveling for a short time.[63]Vaccines are not approved for use in children younger than 2 years. The efficacy of typhoid fever vaccinations againstparatyphiserovars has not been firmly established, but is markedly less than their efficacy againsttyphi.[64]Travelers should be vaccinated at least one week prior to departing for an endemic area. Because typhoid vaccines lose effectiveness after several years, consultation with a specialist in travel medicine is advised if the individual is traveling several years after vaccination. In addition, clinicians should warn travelers to consume only safe foods and beverages, because typhoid vaccines offer only moderate protection, and large inocula ofS typhi can overcome vaccine-induced protection.The only absolute contraindication to vaccination is a history of severe local or systemic reactions following a previous dose. The typhoid vaccines available in the United States have not been studied in pregnant women.Currently, the 3 typhoid fever vaccines include injected Vi capsular polysaccharide (ViCPS; Typhim Vi, Pasteur Merieux) antigen, enteric Ty21a (Vivotif Berna, Swiss Serum and Vaccine Institute) live-attenuated vaccine, and an acetone-inactivated parenteral vaccine (used only in members of the armed forces). The efficacy of both vaccines available to the general public approaches 50%.Vi capsular polysaccharide antigen vaccineVi capsular polysaccharide antigen vaccine is composed of purified Vi antigen, the capsular polysaccharide elaborated byS typhiisolated from blood cultures. The Vi antigen is absent inS paratyphi A, but this vaccine does provide some in vitro immunogenicity againstS paratyphi A. This may be due to trace amounts of other, common antigens in the preparation.[65]Primary vaccination with ViCPS consists of a single parenteral dose of 0.5 mL (25 g IM) one week before travel. The vaccine manufacturer does not recommend the vaccine for children younger than 2 years. Booster doses are needed every 2 years to maintain protection if continued or renewed exposure is expected.Adverse effects include fever, headache, erythema, and/or induration of 1 cm or greater. In a study conducted in Nepal, the ViCPS vaccine produced fewer local and systemic reactions than the control (the 23-valent pneumococcal vaccine).[66]Among school children in South Africa, ViCPS produced less erythema and induration than the control (bivalent vaccine).A systemic review and meta-analysis of 5 randomized controlled trials on the efficacy and safety of ViCPS versus placebo or nontyphoid vaccine found a cumulative efficacy of 55% (95% CI, 30%-70%).The efficacy of vaccination with ViCPS has not been studied among persons from areas without endemic disease who travel to endemic regions or among children younger than 5 years. ViCPS has not been given to children younger than 1 year.Questions concerning Vi typhoid vaccine effectiveness in young children (ie, < 5 y) have inhibited its use in developing countries. Whether the vaccine is effective under programmatic conditions is also unclear.Sur et al conducted a phase IV effectiveness trial in slum-dwelling residents aged 2 years or older in India to determine vaccine protection. Participants (n=37,673) were randomly assigned to receive a single dose of either Vi vaccine or inactivated hepatitis A vaccine, according to geographic clusters. The mean rate of Vi vaccine coverage was 61% and 60% for the hepatitis A vaccine.Typhoid fever was diagnosed in 96 subjects in the hepatitis A vaccine group compared with 34 in the Vi vaccine group (no more than 1 episode was reported per individual). Protective effect for typhoid with the Vi vaccine was 61% (P< 0.001) compared with the hepatitis A vaccine group. Children vaccinated while aged 2-5 years had an 80% protection level. Unvaccinated members of the Vi vaccine clusters showed a protection level of 44%. The overall protection level with all Vi vaccine cluster residents was 57%. The authors concluded that the Vi vaccine was effective in young children and protected unvaccinated neighbors of Vi vaccinees.[67]Ty21aTy21a is an oral vaccine that contains live attenuatedS typhiTy21a strains in an enteric-coated capsule. The vaccine elicits both serum and intestinal antibodies and cell-mediated immune responses.In the United States, primary vaccination with Ty21a consists of one enteric-coated capsule taken on alternate days to a total of 4 capsules. The capsules must be refrigerated (not frozen), and all 4 doses must be taken to achieve maximum efficacy.The optimal booster schedule has not been determined; however, the longest reported follow-up study of vaccine trial subjects indicated that efficacy continued for 5 years after vaccination. The manufacturer recommends revaccination with the entire 4-dose series every 5 years if continued or renewed exposure toS typhiis expected. This vaccine may be inactivated if given within 3 days of antibiotics.Adverse effects are rare. They include abdominal discomfort, nausea, vomiting, fever, headache, and rash orurticaria.The vaccine manufacturer of Ty21a recommends against use in children younger than 6 years. It should not be administered to immunocompromised persons; the parenteral vaccines present theoretically safer alternatives for this group.A systemic review and meta-analysis of 4 randomized controlled trials on the efficacy and safety of Ty21a versus placebo or nontyphoid vaccine found a cumulative efficacy of 51% (95% CI, 36%-62%).The efficacy of Ty21a has not been studied among persons from areas without endemic disease who travel to disease-endemic regions.Acetone-inactivated parenteral vaccineAcetone-inactivated parenteral vaccine is currently available only to members of the US Armed Forces. Efficacy rates for this vaccine range from 75%-94%. Booster doses should be administered every 3 years if continued or renewed exposure is expected.The parenteral heat-phenolinactivated vaccine (Wyeth-Ayerst) has been discontinued.No information has been reported concerning the use of one vaccine as a booster after primary vaccination with a different vaccine. However, using either the series of 4 doses of Ty21a or 1 dose of ViCPS for persons previously vaccinated with parenteral vaccine is a reasonable alternative to administration of a booster dose of parenteral inactivated vaccine.A more effective vaccine may be on the horizon. An investigational vaccine using ViCPS conjugated to the nontoxic recombinant pseudomonas exotoxin A (Vi-rEPA) has been studied in a randomized controlled trial. The vaccine was given to children aged 2-5 years and showed an efficacy of 89% (95% CI, 76%-97%) after 3.8 years. Vi-rEPA has not been approved for use in the United States.ComplicationsIn the past 2 decades, reports from disease-endemic areas have documented a wide spectrum of neuropsychiatric manifestations of typhoid fever. Potential neuropsychiatric manifestations of typhoid fever include the following: A toxic confusional state, characterized by disorientation, delirium, and restlessness, is characteristic of late-stage typhoid fever. In some cases, these and other neuropsychiatric features dominate the clinical picture at an early stage. Facial twitching or convulsions may be the presenting feature. Meningismus is not uncommon, but frank meningitis is rare. Encephalomyelitis may develop, and the underlying pathology may be that of demyelinating leukoencephalopathy. In rare cases, transverse myelitis, polyneuropathy, or cranial mononeuropathy develops. Stupor, obtundation, or coma indicates severe disease. Focal intracranial infections are uncommon, but multiplebrain abscesseshave been reported.[68] Other less-common neuropsychiatric manifestations events have included spastic paraplegia, peripheral or cranial neuritis, Guillain-Barr syndrome, schizophrenialike illness, mania, and depression.Respiratory complications may include the following: Cough Ulceration of posterior pharynx Occasional presentation as acute lobar pneumonia (pneumotyphoid)Cardiovascular complications may include the following: Nonspecific electrocardiographic changes occur in 10%-15% of patients with typhoid fever. Toxic myocarditis occurs in 1%-5% of persons with typhoid fever and is a significant cause of death in endemic countries. Toxic myocarditis occurs in patients who are severely ill and toxemic and is characterized by tachycardia, weak pulse and heart sounds, hypotension, and electrocardiographic abnormalities. Pericarditis is rare, but peripheral vascular collapse without other cardiac findings is increasingly described. Pulmonary manifestations have also been reported in patients with typhoid fever.[69]Hepatobiliary complications may include the following: Mild elevation of transaminases without symptoms is common in persons with typhoid fever. Jaundice may occur in persons with typhoid fever and may be due to hepatitis,cholangitis,cholecystitis, or hemolysis. Pancreatitis and accompanying acute renal failure and hepatitis with hepatomegaly have been reported.[70]Intestinal manifestations may include the following: The 2 most common complications of typhoid fever include intestinal hemorrhage (12% in one British series) and perforation (3%-4.6% of hospitalized patients). From 1884-1909 (ie, preantibiotic era), the mortality rate in patients with intestinal perforation due to typhoid fever was 66%-90% but is now significantly lower. Approximately 75% of patients have guarding, rebound tenderness, and rigidity, particularly in the right lower quadrant. Diagnosis is particularly difficult in the approximately 25% of patients with perforation and peritonitis who do not have the classic physical findings. In many cases, the discovery of free intra-abdominal fluid is the only sign of perforation.Genitourinary manifestations may include the following: Approximately 25% of patients with typhoid fever excreteS typhiin their urine at some point during their illness. Immune complex glomerulitis[71]andproteinuriahave been reported, and IgM, C3 antigen, andS typhiantigen can be demonstrated in the glomerular capillary wall. Nephritic syndrome may complicate chronicS typhibacteremia associated with urinaryschistosomiasis. Nephrotic syndromemay occur transiently in patients withglucose-6-phosphate dehydrogenase deficiency. Cystitis: Typhoid cystitis is very rare. Retention of urine in the typhoid state may facilitate infection with coliforms or other contaminants.Hematologic manifestations may include the following: Subclinical disseminated intravascular coagulation is common in persons with typhoid fever. Hemolytic-uremic syndromeis rare.[72] Hemolysis may also be associated with glucose-6-phosphate dehydrogenase deficiency.Musculoskeletal and joint manifestations may include the following: Skeletal muscle characteristically shows Zenker degeneration, particularly affecting the abdominal wall and thigh muscles. Clinically evidentpolymyositismay occur.[73] Arthritisis very rare and most often affects the hip, knee, or ankle.Late sequelae (rare in untreated patients and exceedingly rare in treated patients) may include the following: Neurologic - Polyneuritis, paranoid psychosis, orcatatonia[74] Cardiovascular - Thrombophlebitis of lower-extremity veins Genitourinary -Orchitis Musculoskeletal - Periostitis, often abscesses of the tibia and ribs; spinal abscess (typhoid spine; very rare)PrognosisThe prognosis among persons with typhoid fever depends primarily on the speed of diagnosis and initiation of correct treatment. Generally, untreated typhoid fever carries a mortality rate of 10%-20%. In properly treated disease, the mortality rate is less than 1%.An unspecified number of patients experience long-term or permanent complications, including neuropsychiatric symptoms and high rates of gastrointestinal cancers.Patient EducationBecause vigilant hand hygiene, vaccination, and the avoidance of risky foods and beverages are mainstays of prevention, educating travelers before they enter a disease-endemic region is important.Because the protection offered by vaccination is at best partial, close attention to personal, food, and water hygiene should be maintained. The US Centers for Disease Control and Prevention dictum to "boil it, cook it, peel it, or forget it" is a good rule in any circumstance. If disease occurs while abroad despite these precautions, one can usually call the US consulate for a list of recommended doctors.For excellent patient education resources, see eMedicineHealth's patient education articleForeign Travel.Case studyA wealthy middle-aged man presented to his physician a few days after the onset of flulike symptoms, including fever, myalgias, chills, severe abdominal pain, and a cough, in addition to severe abdominal pain. Over the next 2 weeks, he lost a great deal of weight. He had intermittent but ever-increasing fevers. About 3 weeks after the onset of symptoms, he developed a few pale, salmon-colored macules on his trunk. His cough became much more frequent and severe. He became delirious, listlessly wandering around the house fiddling with doorknobs. During the fourth week of his illness, he rapidly declined with increasing somnolence. After nearly 4 weeks of illness, he died surrounded by his loving family.The patient was Prince Albert, the Consort to Queen Victoria. He was diagnosed with typhoid fever. His personal physician, Sir William Jenner, a leading expert on the disease, diagnosed typhoid fever. Prince Albert received the best therapy of the day.For the most up-to-date information, visit the Centers for Disease Control and Prevention Travelers' Health Typhoid resource (www.cdc.gov/travel) or call the Travelers' Health automated information line at 877-FYI-TRIP. The World Health Organizations site (www.who.int/ith), International Society of Travel Medicine site (www.istm.org), and Travel Doctor (www.traveldoctor.co.uk/diseases.htm) contain useful information as well, though the authors disagree with some of the WHOs antibiotic guidelines.

1. Papagrigorakis MJ, Synodinos PN, Yapijakis C. Ancient typhoid epidemic reveals possible ancestral strain of Salmonella enterica serovar Typhi.Infect Genet Evol. Jan 2007;7(1):126-7.[Medline].[Full Text].2. Christie AB.Infectious Diseases: Epidemiology and Clinical Practice. 4thed. Edinburgh, Scotland: Churchill Livingstone; 1987.3. Raffatellu M, Chessa D, Wilson RP, Tkel C, Akelik M, Bumler AJ. Capsule-mediated immune evasion: a new hypothesis explaining aspects of typhoid fever pathogenesis.Infect Immun. Jan 2006;74(1):19-27.[Medline].4. Parry CM, Hien TT, Dougan G, et al. Typhoid fever.N Engl J Med. Nov 28 2002;347(22):1770-82.[Medline].[Full Text].5. de Jong HK, Parry CM, van der Poll T, Wiersinga WJ. Host-pathogen interaction in invasive Salmonellosis.PLoS Pathog. 2012;8(10):e1002933.[Medline].[Full Text].6. Ramsden AE, Mota LJ, Mnter S, Shorte SL, Holden DW. The SPI-2 type III secretion system restricts motility of Salmonella-containing vacuoles.Cell Microbiol. Oct 2007;9(10):2517-29.[Medline].7. Gonzalez-Escobedo G, Gunn JS. Gallbladder epithelium as a niche for chronic Salmonella carriage.Infect Immun. Aug 2013;81(8):2920-30.[Medline].[Full Text].8. Chiou CS, Wei HL, Mu JJ, Liao YS, Liang SY, Liao CH, et al. Salmonella enterica serovar Typhi variants in long-term carriers.J Clin Microbiol. Feb 2013;51(2):669-72.[Medline].[Full Text].9. Levine MM, Tacket CO, Sztein MB. Host-Salmonella interaction: human trials.Microbes Infect. Nov-Dec 2001;3(14-15):1271-9.[Medline].10. Earampamoorthy S, Koff RS. Health hazards of bivalve-mollusk ingestion.Ann Intern Med. Jul 1975;83(1):107-10.[Medline].[Full Text].11. Ali S, Vollaard AM, Widjaja S, Surjadi C, van de Vosse E, van Dissel JT. PARK2/PACRG polymorphisms and susceptibility to typhoid and paratyphoid fever.Clin Exp Immunol. Jun 2006;144(3):425-31.[Medline].12. Ram PK, Naheed A, Brooks WA, Hossain MA, Mintz ED, Breiman RF. Risk factors for typhoid fever in a slum in Dhaka, Bangladesh.Epidemiol Infect. Apr 2007;135(3):458-65.[Medline].13. Karkey A, Thompson CN, Tran Vu Thieu N, Dongol S, Le Thi Phuong T, Voong Vinh P, et al. Differential epidemiology of Salmonella Typhi and Paratyphi A in Kathmandu, Nepal: a matched case control investigation in a highly endemic enteric fever setting.PLoS Negl Trop Dis. 2013;7(8):e2391.[Medline].[Full Text].14. Vollaard AM, Ali S, van Asten HA, Widjaja S, Visser LG, Surjadi C, et al. Risk factors for typhoid and paratyphoid fever in Jakarta, Indonesia.JAMA. Jun 2 2004;291(21):2607-15.[Medline].15. Gotuzzo E, Frisancho O, Sanchez J, Liendo G, Carrillo C, Black RE, et al. Association between the acquired immunodeficiency syndrome and infection with Salmonella typhi or Salmonella paratyphi in an endemic typhoid area.Arch Intern Med. Feb 1991;151(2):381-2.[Medline].16. Manfredi R, Chiodo F. Salmonella typhi disease in HIV-infected patients: case reports and literature review.Infez Med. 1999;7(1):49-53.[Medline].17. Gordon MA, Graham SM, Walsh AL, Wilson L, Phiri A, Molyneux E, et al. Epidemics of invasive Salmonella enterica serovar enteritidis and S. enterica Serovar typhimurium infection associated with multidrug resistance among adults and children in Malawi.Clin Infect Dis. Apr 1 2008;46(7):963-9.[Medline].18. Monack DM, Mueller A, Falkow S. Persistent bacterial infections: the interface of the pathogen and the host immune system.Nat Rev Microbiol. Sep 2004;2(9):747-65.[Medline].19. van de Vosse E, Ali S, de Visser AW, Surjadi C, Widjaja S, Vollaard AM, et al. Susceptibility to typhoid fever is associated with a polymorphism in the cystic fibrosis transmembrane conductance regulator (CFTR).Hum Genet. Oct 2005;118(1):138-40.[Medline].20. Poolman EM, Galvani AP. Evaluating candidate agents of selective pressure for cystic fibrosis.J R Soc Interface. Feb 22 2007;4(12):91-8.[Medline].21. Dutta TK, Beeresha, Ghotekar LH. Atypical manifestations of typhoid fever.J Postgrad Med. Oct-Dec 2001;47(4):248-51.[Medline].22. Lynch MF, Blanton EM, Bulens S, Polyak C, Vojdani J, Stevenson J. Typhoid fever in the United States, 1999-2006.JAMA. Aug 26 2009;302(8):859-65.[Medline].23. Chau TT, Campbell JI, Galindo CM, Van Minh Hoang N, Diep TS, Nga TT, et al. Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.Antimicrob Agents Chemother. Dec 2007;51(12):4315-23.[Medline].24. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever.Bull World Health Organ. May 2004;82(5):346-53.[Medline].25. Crump JA, Ram PK, Gupta SK, Miller MA, Mintz ED. Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005.Epidemiol Infect. Apr 2008;136(4):436-48.[Medline].26. Mulligan TO. Typhoid fever in young children.Br Med J. Dec 11 1971;4(5788):665-7.[Medline].27. Rahaman MM, Jamiul AK. Rose spots in shigellosis caused by Shigella dysenteriae type 1 infection.Br Med J. Oct 29 1977;2(6095):1123-4.[Medline].28. Cunha BA. Malaria or typhoid fever: a diagnostic dilemma?.Am J Med. Dec 2005;118(12):1442-3; author reply 1443-4.[Medline].29. Woodward TE, Smadel JE. Management of typhoid fever and its complications.Ann Intern Med. Jan 1964;60:144-57.[Medline].30. Hermans P, Gerard M, van Laethem Y, et al. Pancreatic disturbances and typhoid fever.Scand J Infect Dis. 1991;23(2):201-5.[Medline].31. Butler T, Islam A, Kabir I, et al. Patterns of morbidity and mortality in typhoid fever dependent on age and gender: review of 552 hospitalized patients with diarrhea.Rev Infect Dis. Jan-Feb 1991;13(1):85-90.[Medline].32. Butler T, Knight J, Nath SK, et al. Typhoid fever complicated by intestinal perforation: a persisting fatal disease requiring surgical management.Rev Infect Dis. Mar-Apr 1985;7(2):244-56.[Medline].33. Crum NF. Current trends in typhoid Fever.Curr Gastroenterol Rep. Aug 2003;5(4):279-86.[Medline].34. Huang DB, DuPont HL. Problem pathogens: extra-intestinal complications of Salmonella enterica serotype Typhi infection.Lancet Infect Dis. Jun 2005;5(6):341-8.[Medline].35. Abdel Wahab MF, el-Gindy IM, Sultan Y, el-Naby HM. Comparative study on different recent diagnostic and therapeutic regimens in acute typhoid fever.J Egypt Public Health Assoc. 1999;74(1-2):193-205.[Medline].36. Wain J, Pham VB, Ha V, Nguyen NM, To SD, Walsh AL, et al. Quantitation of bacteria in bone marrow from patients with typhoid fever: relationship between counts and clinical features.J Clin Microbiol. Apr 2001;39(4):1571-6.[Medline].37. Escamilla J, Florez-Ugarte H, Kilpatrick ME. Evaluation of blood clot cultures for isolation of Salmonella typhi, Salmonella paratyphi-A, and Brucella melitensis.J Clin Microbiol. Sep 1986;24(3):388-90.[Medline].38. Gilman RH, Terminel M, Levine MM, Hernandez-Mendoza P, Hornick RB. Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever.Lancet. May 31 1975;1(7918):1211-3.[Medline].39. Farooqui BJ, Khurshid M, Ashfaq MK, Khan MA. Comparative yield of Salmonella typhi from blood and bone marrow cultures in patients with fever of unknown origin.J Clin Pathol. Mar 1991;44(3):258-9.[Medline].40. Ambati SR, Nath G, Das BK. Diagnosis of typhoid fever by polymerase chain reaction.Indian J Pediatr. Oct 2007;74(10):909-13.[Medline].41. Song JH, Cho H, Park MY, et al. Detection of Salmonella typhi in the blood of patients with typhoid fever by polymerase chain reaction.J Clin Microbiol. Jun 1993;31(6):1439-43.[Medline].42. Sadallah F, Brighouse G, Del Giudice G, et al. Production of specific monoclonal antibodies to Salmonella typhi flagellin and possible application to immunodiagnosis of typhoid fever.J Infect Dis. Jan 1990;161(1):59-64.[Medline].43. Balasubramanian S, Kaarthigeyan K, Srinivas S, Rajeswari R. Serum ALT: LDH Ratio in Typhoid Fever and Acute Viral Hepatitis.Indian Pediatr. Jul 1 2009;[Medline].44. Capoor MR, Nair D, Deb M, Aggarwal P. Enteric fever perspective in India: emergence of high-level ciprofloxacin resistance and rising MIC to cephalosporins.J Med Microbiol. Aug 2007;56:1131-2.[Medline].45. Pai H, Byeon JH, Yu S, Lee BK, Kim S. Salmonella enterica serovar typhi strains isolated in Korea containing a multidrug resistance class 1 integron.Antimicrob Agents Chemother. Jun 2003;47(6):2006-8.[Medline].46. Mamun KZ, Tabassum S, Ashna SM, Hart CA. Molecular analysis of multi-drug resistant Salmonella typhi from urban paediatric population of Bangladesh.Bangladesh Med Res Counc Bull. Dec 2004;30(3):81-6.[Medline].47. Ahmed D, D'Costa LT, Alam K, Nair GB, Hossain MA. Multidrug-resistant Salmonella enterica serovar typhi isolates with high-level resistance to ciprofloxacin in Dhaka, Bangladesh.Antimicrob Agents Chemother. Oct 2006;50(10):3516-7.[Medline].48. Zhanel GG, Smith HJ. Flouroquinolone resistance-associated gene mutations in Streptococcus pneumoniae. In: Fuchs J, Podda M, eds.Encyclopedia of Medical Genomics and Proteomics. CRC Press; 2004:497-8.[Full Text].49. Turner AK, Nair S, Wain J. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.J Antimicrob Chemother. Oct 2006;58(4):733-40.[Medline].50. Effa EE, Lassi ZS, Critchley JA, et al. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever).Cochrane Database Syst Rev. Oct 5 2011;CD004530.[Medline].51. Arjyal A, Pandit A. Treatment of enteric fever.J Infect Dev Ctries. Dec 1 2008;2(6):426-30.[Medline].52. Kundu R, Ganguly N, Ghosh TK, et al. IAP Task Force Report: management of enteric fever in children.Indian Pediatr. Oct 2006;43(10):884-7.[Medline].53. Islam MN, Rahman ME, Rouf MA, Islam MN, Khaleque MA, Siddika M, et al. Efficacy of azithromycin in the treatment of childhood typhoid Fever.Mymensingh Med J. Jul 2007;16(2):149-53.[Medline].54. Acosta C et al.Background document: The diagnosis, treatment and prevention of typhoid fever. Geneva, Switzerland: World Health Organization; 07/2003. Vaccines and Biologicals.[Full Text].55. National Antimicrobial Resistance Monitoring System 2012 Human Isolates Final Report. Available athttp://www.cdc.gov/narms/pdf/2012-annual-report-narms-508c.pdf.56. Dutta S, Sur D, Manna B, Bhattacharya SK, Deen JL, Clemens JD. Rollback of Salmonella enterica serotype Typhi resistance to chloramphenicol and other antimicrobials in Kolkata, India.Antimicrob Agents Chemother. Apr 2005;49(4):1662-3.[Medline].57. Vaccines and Biologicals. Geneva, Switzerland: World Health Organization; May, 2003.58. Cooke FJ, Wain J. The emergence of antibiotic resistance in typhoid fever.Travel Med Infect Dis. May 2004;2(2):67-74.[Medline].59. Trivedi NA, Shah PC. A meta-analysis comparing the safety and efficacy of azithromycin over the alternate drugs used for treatment of uncomplicated enteric fever.J Postgrad Med. Apr 2012;58(2):112-8.[Medline].60. Hoffman SL, Punjabi NH, Kumala S, et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone.N Engl J Med. Jan 12 1984;310(2):82-8.[Medline].61. Bhutta ZA. Current concepts in the diagnosis and treatment of typhoid fever.BMJ. Jul 8 2006;333(7558):78-82.[Medline].62. Rogerson SJ, Spooner VJ, Smith TA, et al. Hydrocortisone in chloramphenicol-treated severe typhoid fever in Papua New Guinea.Trans R Soc Trop Med Hyg. Jan-Feb 1991;85(1):113-6.[Medline].63. Jackson BR, Iqbal S, Mahon B. Updated recommendations for the use of typhoid vaccine - advisory committee on immunization practices, United States, 2015.MMWR Morb Mortal Wkly Rep. Mar 27 2015;64(11):305-8.[Medline].64. Schwartz E, Shlim DR, Eaton M, Jenks N, Houston R. The effect of oral and parenteral typhoid vaccination on the rate of infection with Salmonella typhi and Salmonella paratyphi A among foreigners in Nepal.Arch Intern Med. Feb 1990;150(2):349-51.[Medline].65. Pakkanen SH, Kantele JM, Kantele A. Cross-reactive immune response induced by the vi capsular polysaccharide typhoid vaccine against salmonella paratyphi strains.Scand J Immunol. Mar 2014;79(3):222-9.[Medline].66. Acharya IL, Lowe CU, Thapa R, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report.N Engl J Med. Oct 29 1987;317(18):1101-4.[Medline].67. [Best Evidence] Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.N Engl J Med. Jul 23 2009;361(4):335-44.[Medline].68. Hanel RA, Araujo JC, Antoniuk A, et al. Multiple brain abscesses caused by Salmonella typhi: case report.Surg Neurol. Jan 2000;53(1):86-90.[Medline].69. Koul PA, Wani JI, Wahid A, et al. Pulmonary manifestations of multidrug-resistant typhoid fever.Chest. Jul 1993;104(1):324-5.[Medline].70. Khan M, Coovadia Y, Sturm AW. Typhoid fever complicated by acute renal failure and hepatitis: case reports and review.Am J Gastroenterol. Jun 1998;93(6):1001-3.[Medline].71. Sitprija V, Pipantanagul V, Boonpucknavig V, et al. Glomerulitis in typhoid fever.Ann Intern Med. Aug 1974;81(2):210-3.[Medline].72. Baker NM, Mills AE, Rachman I, et al. Haemolytic-uraemic syndrome in typhoid fever.Br Med J. Apr 13 1974;2(5910):84-7.[Medline].73. Naidoo PM, Yan CC. Typhoid polymyositis.S Afr Med J. Nov 8 1975;49(47):1975-6.[Medline].74. Breakey WR, Kala AK. Typhoid catatonia responsive to ECT.Br Med J. Aug 6 1977;2(6083):357-9.[Medline].75. Ackers ML, Puhr ND, Tauxe RV, et al. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise.JAMA. May 24-31 2000;283(20):2668-73.[Medline].[Full Text].76. Adam D. Use of quinolones in pediatric patients.Rev Infect Dis. Jul-Aug 1989;11 Suppl 5:S1113-6.[Medline].77. Akalin HE. Quinolones in the treatment of typhoid fever.Drugs. 1999;58 Suppl 2:52-4.[Medline].78. Ambrosch F, Fritzell B, Gregor J, et al. Combined vaccination against yellow fever and typhoid fever: a comparative trial.Vaccine. May 1994;12(7):625-8.[Medline].79. Anand AC, Kataria VK, Singh W, et al. Epidemic multiresistant enteric fever in eastern India.Lancet. Feb 10 1990;335(8685):352.[Medline].80. Angorn IB, Pillay SP, Hegarty M, et al. Typhoid perforation of the ileum: A therapeutic dilemma.S Afr Med J. May 3 1975;49(19):781-4.[Medline].81. Cunha BA.Antibiotic Essentials. 7th Ed. Royal Oak, MI: Physicians Press; 2008.82. Archampong EQ. Operative treatment of typhoid perforation of the bowel.Br Med J. Aug 2 1969;3(5665):273-6.[Medline].83. Ashcroft MT, Singh B, Nicholson CC, et al. A seven-year field trial of two typhoid vaccines in Guyana.Lancet. Nov 18 1967;2(7525):1056-9.[Medline].84. Bitar R, Tarpley J. Intestinal perforation in typhoid fever: a historical and state-of-the-art review.Rev Infect Dis. Mar-Apr 1985;7(2):257-71.[Medline].85. Blaser MJ, Hickman FW, Farmer JJ 3rd, et al. Salmonella typhi: the laboratory as a reservoir of infection.J Infect Dis. Dec 1980;142(6):934-8.[Medline].86. Blaser MJ, Newman LS. A review of human salmonellosis: I. Infective dose.Rev Infect Dis. Nov-Dec 1982;4(6):1096-106.[Medline].87. Bodhidatta L, Taylor DN, Thisyakorn U, et al. Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine.Rev Infect Dis. Jul-Aug 1987;9(4):841-5.[Medline].88. Brumell JH, Grinstein S. Salmonella redirects phagosomal maturation.Curr Opin Microbiol. Feb 2004;7(1):78-84.[Medline].[Full Text].89. Butler T, Rumans L, Arnold K. Response of typhoid fever caused by chloramphenicol-susceptible and chloramphenicol-resistant strains of Salmonella typhi to treatment with trimethoprim-sulfamethoxazole.Rev Infect Dis. Mar-Apr 1982;4(2):551-61.[Medline].90. Calva JJ, Ruiz-Palacios GM. Salmonella hepatitis: detection of salmonella antigens in the liver of patients with typhoid fever.J Infect Dis. Aug 1986;154(2):373-4.[Medline].91. Cancellieri V, Fara GM. Demonstration of specific IgA in human feces after immunization with live Ty21a Salmonella typhi vaccine.J Infect Dis. Mar 1985;151(3):482-4.[Medline].92. Capoor MR, Rawat D, Nair D, Hasan AS, Deb M, Aggarwal P, et al. In vitro activity of azithromycin, newer quinolones and cephalosporins in ciprofloxacin-resistant Salmonella causing enteric fever.J Med Microbiol. Nov 2007;56:1490-4.[Medline].93. Carcelen A, Chirinos J, Yi A. Furazolidone and chloramphenicol for treatment of typhoid fever.Scand J Gastroenterol Suppl. 1989;169:19-23.[Medline].94. Centers for Disease Control and Prevention. CDC Typhoid Immunization Recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR. 1994;43(RR-14):1-7.95. Coovadia YM, Gathiram V, Bhamjee A, et al. An outbreak of multiresistant Salmonella typhi in South Africa.Q J Med. Feb 1992;82(298):91-100.[Medline].96. Crosa JH, Brenner DJ, Ewing WH, et al. Molecular relationships among the Salmonelleae.J Bacteriol. Jul 1973;115(1):307-15.[Medline].97. Cryz SJ Jr. Post-marketing experience with live oral Ty21a vaccine.Lancet. Jan 2 1993;341(8836):49-50.[Medline].98. Cumberland NS, St Clair Roberts J, Arnold WS, et al. Typhoid Vi: a less reactogenic vaccine.J Int Med Res. Jun 1992;20(3):247-53.[Medline].99. Cunha BA. Osler on typhoid fever: differentiating typhoid from typhus and malaria.Infect Dis Clin North Am. Mar 2004;18(1):111-25.[Medline].100. Cunha BA. Typhoid fever: the temporal relations of key clinical diagnostic points.Lancet Infect Dis. Jun 2006;6(6):318-20; author reply 320-1.[Medline].101. Dashti AA, Jadaon MM, Habeeb F, West PW, Panigrahi D, Amyes SG. Salmonella enterica Serotype typhi in Kuwait and its reduced susceptibility to ciprofloxacin.J Chemother. Jun 2008;20(3):297-302.[Medline].102. Djemgou PC, Gatsing D, Hegazy ME, El-Hamd Mohamed AH, Ngandeu F, Tane P, et al. Turrealabdane, turreanone and an antisalmonellal agent from Turraeanthus africanus.Planta Med. Feb 2010;76(2):165-71.[Medline].103. Dong B, Galindo CM, Shin E, Acosta CJ, Page AL, Wang M, et al. Optimizing typhoid fever case definitions by combining serological tests in a large population study in Hechi City, China.Epidemiol Infect. Aug 2007;135(6):1014-20.[Medline].104. Duggan MB, Beyer L. Enteric fever in young Yoruba children.Arch Dis Child. Jan 1975;50(1):67-71.[Medline].105. Dunne EF, Fey PD, Kludt P, et al. Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC beta-lactamase.JAMA. Dec 27 2000;284(24):3151-6.[Medline].106. Edelman R, Levine MM. Summary of an international workshop on typhoid fever.Rev Infect Dis. May-Jun 1986;8(3):329-49.[Medline].107. Effa EE, Bukirwa H. Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever).Cochrane Database Syst Rev. Oct 8 2008;CD006083.[Medline].108. Farid Z, Higashi GI, Bassily S, et al. Letter: Immune-complex disease in typhoid and paratyphoid fevers.Ann Intern Med. Sep 1975;83(3):432.[Medline].109. Farmer JJ. Enterobacteriaceae: introduction and identification. In: Murray PR, Baron EF, Pfaller MA, eds.Manual of Clinical Microbiology. 6thed. Washington, DC: American Society for Microbiology; 1995:438-49.110. Ferreccio C, Levine MM, Manterola A, Rodriguez G, Rivara I, Prenzel I, et al. Benign bacteremia caused by Salmonella typhi and paratyphi in children younger than 2 years.J Pediatr. Jun 1984;104(6):899-901.[Medline].111. Ferreccio C, Levine MM, Rodriguez H, et al. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area.J Infect Dis. Apr 1989;159(4):766-9.[Medline].112. Ferreccio C, Morris JG, Valdivieso C, et al. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers.J Infect Dis. Jun 1988;157(6):1235-9.[Medline].113. Frenck RW Jr, Nakhla I, Sultan Y, Bassily SB, Girgis YF, David J, et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children.Clin Infect Dis. Nov 2000;31(5):1134-8.[Medline].114. Frenck RW, Nakhla I, Sultan Y, et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children.Clin Infect Dis. 2000;31:134-1138.[Medline].115. Ghosh SK. Typhoid fever in present-day Britain.Public Health. Jan 1974;88(2):71-8.[Medline].116. Gilman RH, Hornick RB, Woodard WE, et al. Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine.J Infect Dis. Dec 1977;136(6):717-23.[Medline].117. Gilman RH, Terminel M, Levine MM, et al. Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose- spot cultures for recovery of Salmonella typhi in typhoid fever.Lancet. May 31 1975;1(7918):1211-3.[Medline].118. Gorden J, Small PL. Acid resistance in enteric bacteria.Infect Immun. Jan 1993;61(1):364-7.[Medline].119. Gordon MA. Salmonella infections in immunocompromised adults.J Infect. Jun 2008;56(6):413-22.[Medline].120. Gotuzzo E, Frisancho O, Sanchez J, Liendo G, Carrillo C, Black RE, et al. Association between the acquired immunodeficiency syndrome and infection with Salmonella typhi or Salmonella paratyphi in an endemic typhoid area.Arch Intern Med. Feb 1991;151(2):381-2.[Medline].121. Gotuzzo E, Guerra JG, Benavente L, et al. Use of norfloxacin to treat chronic typhoid carriers.J Infect Dis. Jun 1988;157(6):1221-5.[Medline].122. Gray LD. Escherichia, Salmonella, Shigella, and Yersinia. In: Murray PR, Baron EJ, Pfaller MA, eds.Manual of Clinical Microbiology. 6thed. Washington, DC: American Society for Microbiology; 1995:450-6.123. Greisman SE, Woodward TE, Hornick RB, Snyder MJ, Carozza FA Jr. Typhoid fever: a study of pathogenesis and physiologic abnormalities.Trans Am Clin Climatol Assoc. 1961;73:146-61.[Medline].124. Gulati S, Marwaha RK, Prakash D, et al. Multi-drug-resistant Salmonella typhi--a need for therapeutic reappraisal.Ann Trop Paediatr. 1992;12(2):137-41.[Medline].125. Gupta A. Multidrug-resistant typhoid fever in children: epidemiology and therapeutic approach.Pediatr Infect Dis J. Feb 1994;13(2):134-40.[Medline].126. Gupta SP, Gupta MS, Bhardwaj S, et al. Current clinical patterns of typhoid fever: a prospective study.J Trop Med Hyg. Dec 1985;88(6):377-81.[Medline].127. Hensel M. Salmonella pathogenicity island 2.Mol Microbiol. Jun 2000;36(5):1015-23.[Medline].128. Herzog C. Chemotherapy of typhoid fever: a review of literature.Infection. 1976;4(3):166-73.[Medline].129. Herzog C. New trends in the chemotherapy of typhoid fever.Acta Trop. Sep 1980;37(3):275-80.[Medline].130. Hoffman SL, Edman DC, Punjabi NH, et al. Bone marrow aspirate culture superior to streptokinase clot culture and 8 ml 1:10 blood-to-broth ratio blood culture for diagnosis of typhoid fever.Am J Trop Med Hyg. Jul 1986;35(4):836-9.[Medline].131. Hoffman SL, Flanigan TP, Klaucke D, et al. The Widal slide agglutination test, a valuable rapid diagnostic test in typhoid fever patients at the Infectious Diseases Hospital of Jakarta.Am J Epidemiol. May 1986;123(5):869-75.[Medline].132. Hoffman SL, Punjabi NH, Rockhill RC, et al. Duodenal string-capsule culture compared with bone-marrow, blood, and rectal-swab cultures for diagnosing typhoid and paratyphoid fever.J Infect Dis. Feb 1984;149(2):157-61.[Medline].133. Hornick RB, DuPont HL, Levine MM, et al. Efficacy of a live oral typhoid vaccine in human volunteers.Dev Biol Stand. 1976;33:89-92.[Medline].134. Hornick RB, Greisman SE, Woodward TE, et al. Typhoid fever: pathogenesis and immunologic control.N Engl J Med. Sep 24 1970;283(13):686-91.[Medline].135. Hornick RB, Greisman SE, Woodward TE, et al. Typhoid fever: pathogenesis and immunologic control. 2.N Engl J Med. Oct 1 1970;283(14):739-46.[Medline].136. Hornick RB, Griesman S. On the pathogenesis of typhoid fever.Arch Intern Med. Mar 1978;138(3):357-9.[Medline].137. Hornick RB, Woodward TE. Appraisal of typhoid vaccine in experimentally infected human subjects.Trans Am Clin Climatol Assoc. 1967;78:70-8.[Medline].138. Huckstep RL. Recent advances in the surgery of typhoid fever.Ann R Coll Surg Engl. Apr 1960;26:207-30.[Medline].139. Huckstep RL.Typhoid Fever and Other Salmonella Infections. Edinburgh, Scotland: Churchill Livingstone; 1962.140. Joshi N, Rajeshwari K, Dubey AP, Singh T, Kaur R. Clinical spectrum of fever of unknown origin among Indian children.Ann Trop Paediatr. Dec 2008;28(4):261-6.[Medline].141. Keitel WA, Bond NL, Zahradnik JM, et al. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines.Vaccine. 1994;12(3):195-9.[Medline].142. Keusch GT. Antimicrobial therapy for enteric infections and typhoid fever: state of the art.Rev Infect Dis. Jan-Feb 1988;10 Suppl 1:S199-205.[Medline].143. Khosla SN. Changing patterns of typhoid (a reappraisal).Asian Med J. 1982;25:185-98.144. Khosla SN. Typhoid hepatitis.Postgrad Med J. Nov 1990;66(781):923-5.[Medline].145. Kim JP, Oh SK, Jarrett F. Management of ileal perforation due to typhoid fever.Ann Surg. Jan 1975;181(1):88-91.[Medline].146. Klotz SA, Jorgensen JH, Buckwold FJ, et al. Typhoid fever. An epidemic with remarkably few clinical signs and symptoms.Arch Intern Med. Mar 1984;144(3):533-7.[Medline].147. Klugman KP, Gilbertson IT, Koornhof HJ, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.Lancet. Nov 21 1987;2(8569):1165-9.[Medline].148. Klugman KP, Koornhof HJ, Robbins JB.Immunogenicity and protective efficacy of Vi vaccine against typhoid fever three years after immunization (abstract). Second Asia-Pacific Symposium on Typhoid Fever and Other Salmonellosis. Bangkok, Thailand: 1994.149. Kohbata S, Yokoyama H, Yabuuchi E. Cytopathogenic effect of Salmonella typhi GIFU 10007 on M cells of murine ileal Peyer's patches in ligated ileal loops: an ultrastructural study.Microbiol Immunol. 1986;30(12):1225-37.[Medline].150. Lesser, CF, Miller, SI. Salmonellosis. In:Harrison's Principles of Internal Medicine. 1. 16thed. 2005:898-902.151. Levine MM, Ferreccio C, Black RE, et al. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation.Lancet. May 9 1987;1(8541):1049-52.[Medline].152. Levine MM, Taylor DN, Ferreccio C. Typhoid vaccines come of age.Pediatr Infect Dis J. Jun 1989;8(6):374-81.[Medline].153. Luby, S, Mintz, E. Typhoid Fever.Health Information for International Travel (CDC). 2005-2006;Web link:[Full Text].154. Ly KT, Casanova JE. Mechanisms of Salmonella entry into host cells.Cell Microbiol. Sep 2007;9(9):2103-11.[Medline].155. Mandal BK. Salmonella infections. In: Manson-Bahr, PEC, Bell DR, Manson P, eds.Manson's Tropical Medicine. 20thed. London, UK: Saunders; 1996:849-63.156. Mandal BK. Modern treatment of typhoid fever.J Infect. Jan 1991;22(1):1-4.[Medline].157. Mani V, Brennand J, Mandal BK. Invasive illness with Salmonella virchow infection.Br Med J. Apr 20 1974;2(5911):143-4.[Medline].158. Maskalyk J. Typhoid fever.CMAJ. Jul 22 2003;169(2):132.[Medline].159. Meier DE, Imediegwu OO, Tarpley JL. Perforated typhoid enteritis: operative experience with 108 cases.Am J Surg. Apr 1989;157(4):423-7.[Medline].160. Murphy JR, Baqar S, Munoz C, et al. Characteristics of humoral and cellular immunity to Salmonella typhi in residents of typhoid-endemic and typhoid-free regions.J Infect Dis. Dec 1987;156(6):1005-9.[Medline].161. Nardiello S, Pizzella T, Russo M, et al. Serodiagnosis of typhoid fever by enzyme-linked immunosorbent assay determination of anti-Salmonella typhi lipopolysaccharide antibodies.J Clin Microbiol. Oct 1984;20(4):718-21.[Medline].162. Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls.Bull World Health Organ. Apr 2008;86(4):260-8.[Medline].[Full Text].163. Osuntokun BO, Bademosi O, Ogunremi K, et al. Neuropsychiatric manifestations of typhoid fever in 959 patients.Arch Neurol. Jul 1972;27(1):7-13.[Medline].164. Parker MT. Salmonella. In: Wilson G, Miles A, Parker MT, eds.Topley and Wilson's Principles of Bacteriology, Virology and Immunity. 7thed. Baltimore, Md: Williams & Wilkins; 1983:332-55.165. Parry CM, Karunanayake L, Coulter JB, Beeching NJ. Test for quinolone resistance in typhoid fever.BMJ. Jul 29 2006;333(7561):260-1.[Medline].166. Parry CM, Threlfall EJ. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae.Curr Opin Infect Dis. Oct 2008;21(5):531-8.[Medline].167. Parry, CM. Epidemiological and Clinical Aspects of Typhoid Fever. In: Mastroeni, P and Maskell, D.Salmonella InfectionsClinical, Immunological, and Molecular Aspects. 1st. Nw York, New York: 2006:1-24/1.[Full Text].168. Pithie AD, Wood MJ. Treatment of typhoid fever and infectious diarrhoea with ciprofloxacin.J Antimicrob Chemother. Dec 1990;26 Suppl F:47-53.[Medline].169. Polish Typhoid Committee. Controlled field trials and laboratory studies on the effectiveness of typhoid vaccines in Poland, 1961-64.Bull World Health Organ. 1966;34(2):211-22.[Medline].170. Punjabi NH, Hoffman SL, Edman DC, et al. Treatment of severe typhoid fever in children with high dose dexamethasone.Pediatr Infect Dis J. Aug 1988;7(8):598-600.[Medline].171. Punjabi NH, Hoffman SL, Edman DC, Sukri N, Laughlin LW, Pulungsih SP, et al. Treatment of severe typhoid fever in children with high dose dexamethasone.Pediatr Infect Dis J. Aug 1988;7(8):598-600.[Medline].172. Raffatellu M, Chessa D, Wilson RP, Dusold R, Rubino S, Bumler AJ. The Vi capsular antigen of Salmonella enterica serotype Typhi reduces Toll-like receptor-dependent interleukin-8 expression in the intestinal mucosa.Infect Immun. Jun 2005;73(6):3367-74.[Medline].173. Ramachandran S, Wickremesinghe HR, Perera MV. Acute disseminated encephalomyelitis in typhoid fever.Br Med